For Nicole Junkermann, Life Sciences Belong to patient Capital Rather Than to Short-Cycle Investors

The life sciences portfolio built by Nicole Junkermann through NJF Capital, the venture arm of NJF Holdings, has been shaped around a criterion that differs from the one prevailing across much of the sector’s risk capital. Rather than backing individual molecules or single-asset bets, NJF Capital has directed its positions towards platforms, data systems and research ecosystems, on the logic that structural value is generated by the system that produces outcomes repeatedly, rather than by an isolated clinical result.

The approach fits within The Human Code framework, the investment philosophy that articulates NJF Holdings‘ activity and which has gained particular weight in its application to biomedicine. According to that principle, the strongest long-term returns come from systems that people can trust and inherit over time, rather than from those that accelerate their scaling in the short term. Transferred to healthcare, the approach favours companies whose thesis rests on the research infrastructure itself, alongside the operational capacity to turn biomedical data into clinically validated decisions.

Patient capital as Nicole Junkermann’s investment criterion

Much of the investor’s position in the sector rests on a mismatch of time horizons. Biology does not conform to conventional financial calendars, and a therapy that runs twelve years from initial hypothesis to patient access does not constitute a market failure, but a process that has followed its clinical and regulatory logic. According to Junkermann‘s reading, the discomfort that many investors express towards the sector stems precisely from evaluating a biotech company with the instruments designed to measure a SaaS business, without recognising that the signals are real but operate on a different clock.

Far from acting as an obstacle, such a mismatch defines the opportunity. Sectors that demand time tend to repel short-term capital, which reduces competition and opens space for investors capable of operating on long horizons and with governance structures compatible with extended timeframes. NJF Capital‘s portfolio in the area includes companies such as Owkin, Cambrian Biopharma and Tempus, positions articulated around platforms and data systems rather than single-molecule bets. The same orientation has also guided the group’s work outside healthcare, including in the sports infrastructure investments channelled through Gameday by NJF Holdings, where the underlying logic of building durable platforms repeats itself in a different sector.

Europe’s structural position in life sciences

The founder of NJF Holdings places Europe in a position of uneven strength when analysing the life sciences landscape. The continent concentrates first-tier universities, an internationally recognised scientific base and a regulatory framework led by the European Medicines Agency that ranks among the world’s most rigorous, alongside a hospital and research network covering more than 500 million people under a shared framework. Despite that combination of strengths, the outcome in commercially scaled companies proves more uneven, with a persistent gap between European research output and the commercial realisation of that research.

The pattern has repeated itself over years with relative stability. Companies founded in Europe raise growth capital in the United States, relocate their headquarters to be closer to investors and end up listing on North American exchanges. The research base remains on the continent, while value creation shifts elsewhere, a dynamic the investor has described as the result of insufficient late-stage capital structures, combined with a lower cultural tolerance for the long, iterative timelines that characterise serious scientific development.

The convergence with artificial intelligence shifts some elements of the picture, although not all of them. Owkin, in particular, operates with a federated approach that allows hospitals and research institutions to collaborate on biomedical data without transferring sensitive patient information, an architecture that turns European data protection standards into a competitive advantage rather than an obstacle. According to Nicole Junkermann, the continent’s clinical depth, combined with the regulatory credibility of institutions like the European Medicines Agency, constitutes the kind of asset that is difficult to replicate in other geographies. The effective deployment of those advantages depends on capital and governance decisions that the continent has yet to take fully.

The application of The Human Code framework to the demographic horizon

The German investor has placed longevity among the prominent axes of the biomedical portfolio, with an explicit distinction from the more speculative versions of the debate. In her reading, longevity as a thesis is only valid to the extent that it is anchored in genuine biology, which orients the interest towards extending healthy years, advanced prevention, cognitive health across a longer life and the construction of better systems for the final stages of life. The demographic argument operates as the underlying basis for the approach, given that the populations of Europe, North America and much of Asia are ageing at a rate the existing healthcare systems were not designed to absorb.

The pressure on those systems is structural rather than cyclical, which places the demand for innovation in a category distinct from that of a market trend. According to Junkermann, the question is not about backing products that consumers might want, but infrastructures that societies will increasingly need, a distinction that has guided more than a decade of NJF Capital‘s work at the intersection between biomedical research, clinical data and long-term capital. The group’s activity in the sector continues in that direction, in line with a pattern that has also found recent validation in other segments of NJF Capital‘s technology portfolio, including the acquisition of Groq by Nvidia.

Similar Stories